Executive record

Mitchel Sayare, Ph.D.

Director at Altimmune, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:mitchel-sayare-ph-dVersion: public-0As of: 2026-09-28

Not yet claimed7 published Claims3 sources
  • Director

Key Claims

Biography

Mitchel Sayare, Ph.D. served as Chairman of ImmunoGen, Inc. from 1989 to 2010 and as CEO from 1986 to 2009. He previously served as Vice President of Development at Xenogen and as Assistant Professor of Biophysics and Biochemistry at the University of Connecticut. He currently serves as chairman of boards of AutoIVF, Inc. and MassPay Holdings, Inc., and is a director of other private companies.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ALT DEF 14A director slate

    sec filing · Source published: Mar 17, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Audit · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Mar 17, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Altimmune, Inc. · Claim reviewed: May 15, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Altimmune, Inc. · Claim reviewed: May 15, 2026